Bjoern Chapuy

2007–2025 年に発表

72
論文数
19,128
被引用数
50
h 指数
66
i10 指数

被引用数

Bjoern Chapuy の年別被引用数2001 年: 被引用 1 件2003 年: 被引用 2 件2004 年: 被引用 1 件2005 年: 被引用 1 件2006 年: 被引用 7 件2008 年: 被引用 3 件2009 年: 被引用 8 件2010 年: 被引用 3 件2011 年: 被引用 23 件2012 年: 被引用 62 件2013 年: 被引用 110 件2014 年: 被引用 159 件2015 年: 被引用 335 件2016 年: 被引用 412 件2017 年: 被引用 453 件2018 年: 被引用 407 件2019 年: 被引用 1,072 件2020 年: 被引用 1,089 件2021 年: 被引用 1,042 件2022 年: 被引用 717 件2023 年: 被引用 562 件2024 年: 被引用 810 件2025 年: 被引用 314 件2026 年: 被引用 9 件2002 年は被引用が無いため表示していません2007 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,623 件、この内訳の 26.8%中国: 引用元論文 1,375 件、この内訳の 14.1%ドイツ: 引用元論文 620 件、この内訳の 6.3%イギリス: 引用元論文 495 件、この内訳の 5.1%イタリア: 引用元論文 495 件、この内訳の 5.1%フランス: 引用元論文 439 件、この内訳の 4.5%カナダ: 引用元論文 342 件、この内訳の 3.5%スペイン: 引用元論文 341 件、この内訳の 3.5%日本: 引用元論文 318 件、この内訳の 3.2%スイス: 引用元論文 272 件、この内訳の 2.8%オーストラリア: 引用元論文 211 件、この内訳の 2.2%オランダ: 引用元論文 208 件、この内訳の 2.1%
0%26.8%その他 20.8%

分野

  • Medicine60.2%
  • Biochemistry, Genetics and Molecular Biology29.9%
  • Immunology and Microbiology8.2%
  • Engineering0.4%
  • Computer Science0.3%
  • Chemistry0.2%
  • その他0.8%

トピック

  • Lymphoma Diagnosis and Treatment9.6%
  • Cancer Immunotherapy and Biomarkers8.6%
  • CAR-T cell therapy research5.9%
  • Immune Cell Function and Interaction5.6%
  • Immunotherapy and Immune Responses3.4%
  • Chronic Lymphocytic Leukemia Research3.1%
  • その他63.8%

共著者

全論文

検索で開く
  1. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Reiner Siebert, Andreas Rosenwald, Aaron R. Thorner, Matthew Meyerson, Todd R. Golub, Rameen Beroukhim, Gerald Wulf, German Ott, Scott J. Rodig, Stefano Monti, Donna Neuberg, Markus Loeffler, Michael Pfreundschuh, Lorenz Trümper, Gad Getz, Margaret A. Shipp - Nature Medicine 2018 被引用: 1,972

  2. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

    著者: , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2014 被引用: 3,547

  3. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

    著者: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 被引用: 803

  4. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

    著者: , , , , , , , , , , , - Blood 2010 被引用: 1,297

  5. Metabolic Signatures Uncover Distinct Targets in Molecular Subsets of Diffuse Large B Cell Lymphoma

    著者: , , , , , , , , , , , , , , , , - Cancer Cell 2012 被引用: 528

  6. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

    著者: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 被引用: 1,011

  7. PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

    著者: , , , , , , , , , , - Clinical Cancer Research 2013 被引用: 839

  8. Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma

    著者: , , , , , , , , , , , , , , , - Cancer Cell 2013 被引用: 766

  9. The proteogenomic subtypes of acute myeloid leukemia

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daniel Hübschmann, Lars Kaderali, Jürgen Cox, Bernhard Brüne, Christoph Röllig, Christian Thiede, Björn Steffen, Martin Bornhäuser, Andreas Trumpp, Henning Urlaub, Kimberly Stegmaier, Hubert Serve, Matthias Mann, Thomas Oellerich - Cancer Cell 2022 被引用: 147

  10. Targetable genetic features of primary testicular and primary central nervous system lymphomas

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Margaret A. Shipp - Blood 2015 被引用: 599

  11. NLRC5/MHC class I transactivator is a target for immune evasion in cancer

    著者: , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2016 被引用: 270

  12. TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , - Nature Cancer 2021 被引用: 117

  13. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma

    著者: , , , , , , , , - Blood 2017 被引用: 459

  14. Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Cell Biology 2020 被引用: 179

  15. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , James R. Cerhan, Margaret A. Shipp, Gad Getz, Todd R. Golub - National Academy of Sciences, Proceedings of the National Academy of Sciences 2012 被引用: 980

  16. Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2022 被引用: 84

  17. Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma

    著者: , , , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2021 被引用: 93

  18. Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status

    著者: , , , , , , , , , , , , , , , - Cancer Immunology Research 2016 被引用: 191

  19. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3

    著者: , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2011 被引用: 359

  20. Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion

    著者: , , , , , , , , , , , , , , , , , , , , , - Blood Advances 2019 被引用: 165

  21. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Francesco Hofmann, Frank C. Kuo, Michael J. Eck, Lewis B. Silverman, Stephen E. Sallan, Anthony Letai, Fabienne Baffert, Eric Vangrevelinghe, Thomas Radimerski, Christoph Gaul, David M. Weinstock - Cancer Cell 2015 被引用: 123

  22. Molecular and clinical diversity in primary central nervous system lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Chip Stewart, Aurélien de Reyniès, Sylvain Choquet, Carole Soussain, Caroline Houillier, Bjoern Chapuy, Khê Hoang‐Xuan, Agustí Alentorn - Annals of Oncology 2022 被引用: 83

  23. EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2020 被引用: 119

  24. Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell–rich and exhausted T-effector microenvironment

    著者: , , , , , , , , , , , , , , , , - Blood 2018 被引用: 165